We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYNNEX Ties Up With Sophos to Strengthen Endpoint Security
Read MoreHide Full Article
SYNNEX Corporation (SNX - Free Report) in a bid to expand its cybersecurity portfolio partnered Sophos, a UK-based global leader in network and endpoint security.
With this partnership, SYNNEX aims to enhance its cybersecurity offerings, thus offering customers top notch security management tools.
Notably, the security solutions provided by Sophos help “organizations of all sizes secure everything from endpoints (laptops, mobile devices and servers) to networks, and web and email traffic.” Further, the company delivers network and endpoint security through a single cloud-based platform called Sophos Central.
At CRN 2019 ARW awards, Sophos has been voted the industry’s best in all three security categories, namely Network, Endpoint and Data apart from all 12 other subcategories owing to its product strength, innovation and channel leadership
Reportedly, SYNNEX will be delivering pre-sales support, training and enablement, demo products and professional services to the resellers that use the new offering.
Sunny Prospects for Endpoint Security
The endpoint security market is benefiting from rampant data breaches in organizations. Further, a spate of unknown and new attacks in endpoint networks is leading to a rapid adoption of endpoint security systems among enterprises. Increasing deployment of IoT and robust demand for smart devices are also key drivers.
Per a Fortune Business Insights report, the endpoint security market is expected to increase from $5.3 billion in 2018 to $10.03 billion in 2026 seeing a CAGR of 8.4%.
In the era of swarming cyberthreats, SYNNEX’s partnership with Sophos is likely to be a key catalyst.
Partnerships to Boost Growth
SYNNEX’s focus on expanding its IT products and services through acquisitions and partnerships is a key driver.
Earlier in March, SYNNEX added services and tools for channel partners in collaboration with Palo Alto Networks (PANW - Free Report) .
Moreover, in July, the company added Arista Network’s (ANET - Free Report) cloud networking portfolio to its line card.
However, fierce competition from Tech Data is a key concern. Recently, Tech Data announced that it is teaming up with Deep Instinct for its end-to-end deep learning framework for cybersecurity.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
SYNNEX Ties Up With Sophos to Strengthen Endpoint Security
SYNNEX Corporation (SNX - Free Report) in a bid to expand its cybersecurity portfolio partnered Sophos, a UK-based global leader in network and endpoint security.
With this partnership, SYNNEX aims to enhance its cybersecurity offerings, thus offering customers top notch security management tools.
Notably, the security solutions provided by Sophos help “organizations of all sizes secure everything from endpoints (laptops, mobile devices and servers) to networks, and web and email traffic.” Further, the company delivers network and endpoint security through a single cloud-based platform called Sophos Central.
At CRN 2019 ARW awards, Sophos has been voted the industry’s best in all three security categories, namely Network, Endpoint and Data apart from all 12 other subcategories owing to its product strength, innovation and channel leadership
Reportedly, SYNNEX will be delivering pre-sales support, training and enablement, demo products and professional services to the resellers that use the new offering.
Sunny Prospects for Endpoint Security
The endpoint security market is benefiting from rampant data breaches in organizations. Further, a spate of unknown and new attacks in endpoint networks is leading to a rapid adoption of endpoint security systems among enterprises. Increasing deployment of IoT and robust demand for smart devices are also key drivers.
Per a Fortune Business Insights report, the endpoint security market is expected to increase from $5.3 billion in 2018 to $10.03 billion in 2026 seeing a CAGR of 8.4%.
In the era of swarming cyberthreats, SYNNEX’s partnership with Sophos is likely to be a key catalyst.
Partnerships to Boost Growth
SYNNEX’s focus on expanding its IT products and services through acquisitions and partnerships is a key driver.
Earlier in March, SYNNEX added services and tools for channel partners in collaboration with Palo Alto Networks (PANW - Free Report) .
Moreover, in July, the company added Arista Network’s (ANET - Free Report) cloud networking portfolio to its line card.
However, fierce competition from Tech Data is a key concern. Recently, Tech Data announced that it is teaming up with Deep Instinct for its end-to-end deep learning framework for cybersecurity.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>